Skip to content

Assessment of the Results of Neurafill Volume Filler Injections to Correction Nasolabial Folds

Evaluation of efficacy and safety of "Neurafill Volume" dermal fillers in correction of Nasolabial folds

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220723055530N2
Enrollment
15
Registered
2023-04-17
Start date
2023-04-09
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin aging.

Interventions

Intervention group: Injection of Neurafill Volume Intradermal gel in the nasolabial folds, the products are in the 1 ml pre-filled sterilized syringe containing:Neurafill Volume:Hyaluronic Acid gel 20

Sponsors

Azar mehr teb parsian
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 60 Years

Inclusion criteria

Inclusion criteria: 25 -60 Years old men and women with moderate to severe nasolabial folds Signing the informed consent form

Exclusion criteria

Exclusion criteria: Having History of a cosmetic procedure in the lower 2/3 of the face during the last three months Presence of active infection, inflammation, unhealed old wound, and skin lesions in the NLF area HavingPrevious allergy to Hyaluronic Acid or Lidocaine History of autoimmune or immune deficiency diseases Individuals prone to hypertrophic scar formation Pregnancy or breastfeeding

Design outcomes

Primary

MeasureTime frame
Severity of nasolabial folds. Timepoint: Before intervention, immediately after that, 2 weeks, and 3 months later. Method of measurement: Five-point photonumeric Allergan scale.

Secondary

MeasureTime frame
Area, depth, and volume of nasolabial folds. Timepoint: Before the intervention, immediately after that, 2 weeks, and 3 months later. Method of measurement: Visioface camera.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Nasimi

Tehran University of Medical Sciences

nsm.maryam@gmail.com+98 21 5563 0223

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026